Market research
3D0A.F Telo Genomics Corp
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 151K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.18
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- CA87975M2085
- Market cap
- 151K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.18
About
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 3D0A.F discussion.
5 years, 4 months ago
Telo Genomics Corp is currently in a long term uptrend where the price is trading 3.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Telo Genomics Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 51.1% to $-274K since the same quarter in the previous year.
Finally, its free cash flow fell by 3132.3% to $-300K since the same quarter in the previous year.
Based on the above factors, Telo Genomics Corp gets an overall score of 3/5.